Convergent Therapeutics, a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, announced the completion of a $90 million Series A financing, led by OrbiMed and RA Capital Management with participation from Invus. The financing will support the development of a pipeline of novel radioantibodies, including its lead program with CONV01-α, for the treatment of advanced prostate cancer.